NCT04203979 Sepsis: From Syndrome to Personalized Care
| NCT ID | NCT04203979 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Sepsis Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,950 participants |
| Start Date | 2020-01-06 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,950 participants in total. It began in 2020-01-06 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, observational study designed to examine the performance of biomarkers, molecular biological methods and other analysis in blood from patient with suspected sepsis in the Emergency department, as well as identidying novel sepsis endotypes. Around 1500 patients will be enrolled.
Eligibility Criteria
Inclusion Criteria: * admitted to emergency department OUH, Ullevål. * managed by the medical rapid response team or the sepsis rapid response team Exclusion Criteria: * Not given informed consent by patient or next of kin (if patient is not able to)
Contact & Investigator
Aleksander R Holten, PhD
PRINCIPAL INVESTIGATOR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT04203979 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04203979 currently recruiting?
Yes, NCT04203979 is actively recruiting participants. Contact the research team at aleksander.holten@gmail.com for enrollment information.
Where is the NCT04203979 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT04203979 clinical trial?
NCT04203979 is sponsored by Oslo University Hospital. The principal investigator is Aleksander R Holten, PhD at Oslo University Hospital. The trial plans to enroll 1,950 participants.